Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182216 | 0.79 | KDM4E (0.67) | TP53CYP3A4CYP2C19TSHRALDH1A1 | |
| SCHEMBL2607466 | 0.75 | KDM4E (0.52) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8599093 | 0.75 | MAPT (0.75) | TP53CYP3A4CYP2C19ALDH1A1MEN1 | |
| SCHEMBL2607735 | 0.73 | KMT2A (0.63) | CYP2C19ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL17824298 | 0.72 | CYP3A4 (0.66) | TP53CYP3A4CYP2C19TSHRALDH1A1 | |
| SCHEMBL2607484 | 0.72 | MAPT (0.61) | TP53ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL2607458 | 0.72 | TP53 (0.53) | TP53TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL2607488 | 0.72 | KMT2A (0.54) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2607447 | 0.72 | KMT2A (0.64) | CYP2C19ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2607486 | 0.72 | KDM4E (0.51) | ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | TP53 3224/4885CYP3A4 226/4885CYP2C19 267/4885 |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | TP53 3224/4885CYP3A4 226/4885CYP2C19 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.